KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Notes Payables (2017 - 2025)

Novartis Ag's Notes Payables history spans 9 years, with the latest figure at $682.0 million for Q4 2025.

  • For Q4 2025, Notes Payables rose 6.23% year-over-year to $682.0 million; the TTM value through Dec 2025 reached $682.0 million, up 6.23%, while the annual FY2025 figure was $682.0 million, 6.23% up from the prior year.
  • Notes Payables for Q4 2025 was $682.0 million at Novartis Ag, up from $642.0 million in the prior quarter.
  • Across five years, Notes Payables topped out at $899.0 million in Q4 2021 and bottomed at $624.0 million in Q4 2023.
  • The 5-year median for Notes Payables is $682.0 million (2025), against an average of $742.0 million.
  • The largest annual shift saw Notes Payables decreased 27.69% in 2023 before it increased 6.23% in 2025.
  • A 5-year view of Notes Payables shows it stood at $899.0 million in 2021, then dropped by 4.0% to $863.0 million in 2022, then dropped by 27.69% to $624.0 million in 2023, then grew by 2.88% to $642.0 million in 2024, then rose by 6.23% to $682.0 million in 2025.
  • Per Business Quant, the three most recent readings for NVS's Notes Payables are $682.0 million (Q4 2025), $642.0 million (Q4 2024), and $624.0 million (Q4 2023).